Pfizer Inc PFE

$29.39 -0.06 (-0.20%)

Valuation

Market cap
170,311,648,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
10.10
P/E (forward)
10.21
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
48,319,500
Avg volume
33,616,914
Day's range
$28.54 – $29.43
Shares out
5,699,854,000
Stochastic %K
29%
Beta
0.31
Analysts
Hold
Price target
$30.20

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

GTA_Terminal Nov 7, 2:48 AM
Dark pool check on $PFE: what traded off the exchanges this session. Price barely moved (-0.2%), which is what you'd expect if somebody big is building or unwinding a position quietly. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=PFE&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=PFE Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-pfizer-pfe?utm_source=stocktwits&utm_medium=social
0 replies
PredictionFLO1 Nov 7, 1:04 AM
See the alerts behind today's flow — 14 days free: https://options.predictionflo.com/trial?via=st_trial_pm Today's board: $QQQ $MU $PFE
0 replies
BioTechHealthX Nov 6, 10:01 PM
$PFE Pfizer Inc. (NYSE: PFE) reported 55% operational growth in Padcev sales and raised its annual outlook. Can cancer medicines give its broader turnaround the momentum investors want? https://biotechhealthx.com/biotech-news/pfizer-pfe-gets-an-oncology-boost-as-padcev-sales-surge-55/
0 replies
PFElinepfrenzy1990 Nov 6, 9:35 PM 0 replies
blakedd5bad Nov 6, 8:49 PM
Drug development through $PFE and AI marketing through $GOAI, two distinct areas I enjoy researching
0 replies
Stocktradesmoon Nov 6, 8:36 PM
$ABCL Phenotype of a company that has the potential to scale up and be the next $REGN $VRTX $LLY $PFE 1. Needs a blockbuster that it wholly owns 2. Capabilities internally to reproducibly develop drugs 3. Pipeline to show its worth more than a single asset - Carl Hansen
0 replies
Stocktradesmoon Nov 6, 8:08 PM
$ABCL ❤️ $REGN $PFE $SLS $MRNA WHO’S EXCITED 😆 for NEXT WEEK?!!!! 😊 ABcellera 🔥!!! 👀🚀 👀🚨 4 MAJOR Catalyst Events All HAPPENING in a few days!! 👀👏🚀 — November could be more important than the recent share price rally. Here’s exactly what I’m watching. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. AND… We got MORE NEWS 🗞️ YESTERDAY After-Hours!! + ABcellera to Present @ the UBS GLOBAL BIOPHARMA Conference on November 17, 2026!!
0 replies
BiotechButterflies Nov 6, 7:38 PM
$PFE LEGOS... the false hope of Pfizer Oncology - was the AMNOG
0 replies